Related Experiment Video
Updated: Jun 9, 2026
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Molecular targeting of intracellular compartments specifically in cancer cells
Hetal Pandya1, Denise M Gibo, Waldemar Debinski
1Departments of Neurosurgery, Radiation Oncology, and Cancer Biology, The Brain Tumor Center of Excellence, Wake Forest University, School of Medicine, Winston-Salem, NC, USA.
Abstract:
We have implemented a strategy in which a genetically engineered, single-chain protein specifically recognizes cancer cells and is trafficked to a targeted subcellular compartment, such as the nucleus. The recombinant protein termed IL-13.E13K-D2-NLS has a triple functional property: (1) it binds a cancer-associated receptor, interleukin 13 receptor alpha 2 (IL-13Rα2), using modified IL-13 ligand, IL-13.E13K; (2) it exports its C-terminal portion out of the endosomal compartment using Pseudomonas aeruginosa exotoxin A (PE) translocation domain (D2); and (3) it travels to and accumulates in the nucleus guided by the nuclear localization signal (NLS). Here, we have demonstrated that this protein is transported into the brain tumor cells' nucleus, using 3 different methods of protein conjugation to dyes for the purpose of direct visualization of the protein's intracellular trafficking. IL-13.E13K-D2-NLS, and not the controls such as IL-13.E13K-D2, IL-13.E13K-NLS, or IL-13.E13K, accumulated in nuclei very efficiently, which increased with the time the cells were exposed to the protein. Also, IL-13.E13K-D2-NLS did not exhibit nuclear transport in cells with low expression levels of IL-13Rα2. Thus, it is possible to recognize cancer cells through their specific receptors and deliver a conjugated protein that travels specifically to the nucleus. Hence, our molecular targeting strategy succeeded in generating a single-chain proteinaceous agent capable of delivering drugs/labels needed to be localized to the cells' nuclei or potentially any other subcellular compartment, for their optimal efficacy or ability to exert their specific action.
Insights
Researchers engineered a protein that targets cancer cells by binding to interleukin 13 receptor alpha 2 (IL-13Rα2) and delivers payloads to the nucleus. This targeted delivery system shows promise for cancer therapy and diagnostics.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Targeting specific cellular compartments is crucial for effective drug delivery and diagnostics.
- Cancer cells often overexpress specific surface receptors, presenting opportunities for targeted therapies.
- Developing engineered proteins for precise intracellular trafficking remains a significant challenge.
Purpose of the Study:
- To engineer a single-chain protein capable of specifically recognizing cancer cells and accumulating in the nucleus.
- To validate the targeted nuclear delivery of the engineered protein in brain tumor cells.
- To establish a novel molecular strategy for delivering therapeutic or diagnostic agents to subcellular locations.
Main Methods:
- Genetic engineering of a single-chain protein (IL-13.E13K-D2-NLS) with IL-13 ligand, exotoxin A translocation domain, and nuclear localization signal.
- Utilizing three distinct protein conjugation methods with dyes for direct visualization of intracellular transport.
- Assessing protein accumulation in nuclei of brain tumor cells and evaluating transport in cells with varying IL-13Rα2 expression levels.
Main Results:
- The engineered protein IL-13.E13K-D2-NLS efficiently accumulated in the nuclei of cancer cells, with increased accumulation over time.
- Control proteins lacking specific functional domains (e.g., IL-13.E13K-D2) did not show significant nuclear accumulation.
- Nuclear transport was dependent on the expression levels of the target receptor IL-13Rα2, with minimal transport in low-expression cells.
Conclusions:
- A genetically engineered protein can specifically target cancer cells via IL-13Rα2 and be efficiently delivered to the nucleus.
- This molecular targeting strategy enables the precise localization of proteinaceous agents to subcellular compartments.
- The developed system holds potential for targeted drug delivery and diagnostic applications in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:56Treatment Resistant Cancers